AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Ardelyx Inc. (ARDX) Boosts Global Presence via Kyowa Kirin Partnership
ByAinvest
Friday, Aug 29, 2025 5:12 am ET1min read
Ardelyx, Inc. (ARDX) reported record prescription volumes and net sales growth in Q2 2025, with revenues reaching $97.7 million. The company strengthened its leadership team and pursues international expansion through partnerships, such as with Kyowa Kirin, to broaden tenapanor's global reach. IBSRELA sales increased 57% YoY, and XPHOZAH also showed strong growth.
Ardelyx, Inc. (ARDX) reported robust financial performance in the second quarter of 2025, with revenues reaching $97.7 million, a 33% year-over-year growth. The company's key products, IBSRELA and XPHOZAH, demonstrated significant sales growth, driving Ardelyx's overall success [1].IBSRELA, a treatment for irritable bowel syndrome with constipation (IBS-C), saw a substantial 84% year-over-year increase in net sales, reaching $65 million. This growth was attributed to increased field activities, effective marketing programs, and expanded reach. Ardelyx raised its full-year 2025 net sales revenue guidance for IBSRELA to $250 million - $260 million, with peak sales expectations exceeding $1 billion [1].
XPHOZAH, a chronic kidney disease (CKD) treatment, showed a 7% increase in net sales compared to Q1 2025, reaching $25 million. The company is navigating the new market landscape for phosphate management, with peak sales expectations remaining at $750 million [1].
Ardelyx also strengthened its leadership team, appointing experienced executives to key roles, including Mike Kelliher as Chief Business Officer and Laura Williams as Chief Patient Officer. The company continues to pursue international expansion, with partnerships like those with Kyowa Kirin to broaden the reach of tenapanor [1].
Despite strong performance, Ardelyx acknowledged certain challenges, including typical summer seasonality impacting prescription trends and the ongoing CMS legal proceedings. The company remains confident in its ability to navigate these dynamics and achieve its financial goals [1].
References:
[1] https://www.datainsightsmarket.com/companies/ARDX
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet